Home › NDC Lookup › RxCUI directory › RxCUI 2121061

Ceritinib 150 MG Oral Tablet [Zykadia] — RxCUI 2121061

RxNorm drug concept · Semantic branded drug
RxCUI 2121061 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2121061
Official nameCeritinib 150 MG Oral Tablet [Zykadia]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asZykadia 150 MG Oral Tablet
FDA products mapped1
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ceritinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Zykadia (ceritinib) is a targeted therapy for a specific type of lung cancer. It's prescribed when your lung cancer has spread (metastatic) and your tumor tests positive for a gene...
  • What exactly is Zykadia and why has my doctor prescribed it for me?
  • Yes, you should take Zykadia with food — that's the recommended way to take the tablet form. Eating when you take it helps reduce stomach side effects like nausea, vomiting, and di...
  • Do I need to take Zykadia with food, and does it matter what I eat?
📖 Read our full Ceritinib guide →

🕸️ Concept Web — How Ceritinib 150 MG Oral Tablet [Zykadia] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Ceritinib 150 MG Oral Tablet [Zykadia] RxCUI 2121061

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ceritinib 1535457
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zykadia 1535463
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ceritinib Oral Tablet 2121058
    • Ceritinib Oral Product 1535459
    • Ceritinib Pill 1535460
    • Ceritinib Oral Tablet [Zykadia] 2121060
    • Zykadia Oral Product 1535466
    • Zykadia Pill 1535467
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Ceritinib 150 MG Oral Tablet SCD · 2121059
  • Ceritinib 150 MG SCDC · 1535458
  • Ceritinib Oral Tablet SCDF · 2121058
  • Ceritinib Oral Product SCDG · 1535459
  • Ceritinib Pill SCDG · 1535460

Brand-Name Concepts

  • Ceritinib 150 MG [Zykadia] SBDC · 1535464
  • Ceritinib Oral Tablet [Zykadia] SBDF · 2121060
  • Zykadia Oral Product SBDG · 1535466
  • Zykadia Pill SBDG · 1535467
  • Zykadia BN · 1535463

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2121061 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-0694-48 21 TABLET, FILM COATED in 1 BOTTLE (0078-0694-48) ZYKADIA Novartis Pharmaceuticals Corporation 2019-03-18
00078-0694-84 84 TABLET, FILM COATED in 1 BOTTLE (0078-0694-84) ZYKADIA Novartis Pharmaceuticals Corporation 2019-03-18
Observed labelers: Novartis Pharmaceuticals Corporation (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.